A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6

por Ji, Jing, Zhang, Zhen, He, Xingbei, Pan, Gang, Li, Guanchu, Lv, Jinyu, Xu, Yuxin, Xie, Mengru, Feng, Jing, Wang, Weiling, Liu, Bin, Ma, Jinming, Wang, Xiujun
Publicado 2023

PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients

por Rong, Xiaoxiang, Lv, Jinyu, Liu, Yantan, Wang, Zhaojun, Zeng, Dongqiang, Li, Yuedan, Li, Shaowei, Wu, Jianhua, Shen, Zheyu, Shi, Min, Liao, Wangjun, Wu, Zhenzhen, Wang, Chunlin
Publicado 2022

Corrigendum: PET/Ct Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients

por Rong, Xiaoxiang, Lv, Jinyu, Liu, Yantan, Wang, Zhaojun, Zeng, Dongqiang, Li, Yuedan, Li, Shaowei, Wu, Jianhua, Shen, Zheyu, Shi, Min, Liao, Wangjun, Wu, Zhenzhen, Wang, Chunlin
Publicado 2022

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6

por Ji, Jing, Liu, Wenwen, Xu, Yuxin, Xu, Zhou, Lv, Mingxiao, Feng, Jing, Lv, Jinyu, He, Xingbei, Zhang, Zhen, Xie, Mengru, Jing, Aixin, Wang, Xiujun, Ma, Jinming, Liu, Bin
Publicado 2023